Clinical trials
Colorectal clinical trials
Below are recruiting colorectal clinical trials, each written for real people, not researchers. We’re tracking 1,218 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT02864485Recruiting
Living donor liver transplant for colorectal cancer spread to the liver
This trial looks at whether a living-donor liver transplant can help people with colorectal cancer that has spread to the liver but cannot be surgically removed. It focuses on people whose cancer has not worsened on prior chemotherapy and who are medically able to undergo a major liver surgery.
Toronto, OntarioAges 18–68 - NCT02246634Recruiting
MRI screening to find liver metastases in bowel cancer
This study checks whether a special MRI scan (DW-MRI) can spot liver metastases early in people with high-risk colorectal cancer. Finding metastases sooner may help doctors choose the right treatment path.
Macclesfield, CheshireAges 16 years+ - NCT02869503Recruiting
Colorectal cancer registry study
This study builds a database of people with colorectal cancer. It may help doctors learn from real-world information to improve future care.
Marseille, Bouches du RhoneAges 18–95 - NCT02885753RecruitingPhase 3
Liver-only metastatic colon cancer trial using targeted chemo
This Phase 3 trial tests different ways to deliver chemotherapy for colon cancer that has spread only to the liver (with limited possible tiny lung spots). It looks at whether the treatment plan improves outcomes compared with another chemotherapy approach, using oxaliplatin and LV5FU2 (with or without irinotecan) plus an added targeted medicine.
BrusselsAges 18 years+ - NCT02919644RecruitingPhase 2
Cancer vaccine made from your own cells after bowel cancer surgery
This trial tests whether a personalized vaccine—made from your own immune cells mixed with your own tumor material—can help prevent colorectal cancer from coming back after curative surgery. It may help your immune system recognize and fight any remaining cancer cells.
Meldola, FCAges 19 years+ - NCT06098560Recruiting
ctDNA as a marker for immunotherapy in advanced colorectal cancer
This study looks at whether a blood test for tumor DNA (ctDNA) can predict how well immunotherapy works in people with advanced or locally advanced colorectal cancer that has specific genetic features (dMMR/MSI-H). If you qualify, the trial will monitor your ctDNA levels while you receive standard immunotherapy to see if changes in those levels can show early on if the treatment is working.
Beijing, Beijing MunicipalityAges 18–80 - NCT06794086RecruitingPhase 3
SBRT and immunotherapy for colorectal cancer liver metastases
This trial combines targeted radiation (SBRT) with an immunotherapy drug (PD-1 inhibitor) to treat colorectal cancer that has spread to the liver and can't be removed by surgery. It aims to help shrink or control tumors in patients whose cancer has a normal DNA repair system (pMMR/MSS).
Guangzhou, GuangdongAges 18–75 - NCT07398326RecruitingPhase 2
Drug combo for advanced colorectal cancer that hasn't spread to the liver
This trial tests a combination of two drugs (anlotinib and sintilimab) as a first treatment for people with advanced colorectal cancer that has spread to places other than the liver, who do not want chemotherapy. The goal is to see if this targeted therapy can help control the cancer.
ShanghaiAges 18 years+ - NCT07411599RecruitingPhase 1/Phase 2
CAR-NK cell therapy plus cetuximab for belly-spread colorectal cancer
This trial tests a new cell therapy (CAR-NK cells given directly into your belly and a vein) combined with a targeted drug (cetuximab) for colorectal cancer that has spread mainly to the lining of your belly. It aims to see if this treatment can shrink tumors and help people who have run out of standard chemotherapy options.
Houston, TexasAges 18 years+ - NCT07417488RecruitingPhase 1
Vaccine therapy for advanced colorectal and small bowel cancer
This trial tests a vaccine therapy for people with advanced colorectal or small bowel cancer that has spread or can't be removed. The vaccine targets a protein found on cancer cells to help your immune system fight the cancer.
Philadelphia, PennsylvaniaAges 18 years+ - NCT07422974Recruiting
Surgery results after pre-treatment for colorectal cancer
This study looks at how well patients recover from colorectal cancer surgery, comparing those who had chemotherapy or radiation before surgery to those who did not. The goal is to understand if pre-treatment affects surgical outcomes.
OsijekAges 18 years+ - NCT07427901Recruiting
Quality of life in colorectal cancer survivors
This study looks at how colorectal cancer and its treatment affect your daily life and well-being. It aims to help doctors better support patients like you during and after treatment.
LjubljanaAges 18 years+ - NCT07450612Recruiting
Blood test and AI for early colorectal cancer detection
This study uses a simple blood test (liquid biopsy) and computer analysis to find early signs of colorectal cancer, precancerous growths, and Lynch syndrome. It aims to improve early detection and monitor for any remaining cancer after treatment.
Milan, LombardyAges 18 years+ - NCT07462143RecruitingPhase 2/Phase 3
New drug plus chemo for advanced colorectal cancer
This trial tests a new drug (RC148) combined with standard chemotherapy as a first treatment for colorectal cancer that has spread or cannot be removed. The goal is to see if this combination works better than chemotherapy alone.
Beijing, Beijing MunicipalityAges 18–75 - NCT07462650RecruitingPhase 1/Phase 2
CAR-NK cell therapy for advanced colorectal cancer
This trial tests a new treatment using modified natural killer cells (CAR-NK) that target two specific proteins found on your cancer cells. It is for people with advanced colorectal cancer who have tried standard treatments without success.
Shenzhen, GuangdongAges 18–75 - NCT07464626Recruiting
Art therapy for anxiety and sleep in colorectal cancer patients
This study compares virtual and in-person art therapy to help reduce anxiety, improve psychological well-being, and enhance sleep quality for people with colorectal cancer who are receiving chemotherapy.
Izmir, BalçovaAges 18 years+ - NCT06012734RecruitingPhase 1
LB-100 plus Atezolizumab for metastatic colorectal cancer
This trial tests a new two-drug combination (LB-100 plus atezolizumab) for people with metastatic colorectal cancer that hasn't responded to standard treatment. The goal is to see if the combination can help shrink or slow the cancer.
Amsterdam, North HollandAges 18 years+ - NCT06714318Recruiting
Using blood samples to improve colorectal cancer screening
This study is looking at whether adding a blood test can make the current stool-based screening for colorectal cancer more accurate. It may help find cancers earlier or reduce the need for colonoscopy.
AabenraaAges 50–74 - NCT07494201Recruiting
MIMICC study for people with colorectal cancer
This trial is studying patients with colorectal cancer who are scheduled for surgery. Researchers want to learn more about the cancer to improve future treatments.
Candiolo, Torino (TO)Ages 18–75 - NCT07500298RecruitingPhase 1
New drug plus standard chemo for spread colorectal cancer
This trial tests a new drug called SAR445877 combined with two standard chemotherapies (FOLFOX and bevacizumab) as an initial treatment for people whose colorectal cancer has spread and is microsatellite stable (MSS). It aims to see if adding this drug works better than standard therapy alone.
Houston, TexasAges 18 years+ - NCT07503756RecruitingPhase 2
JS212 Combination for Untreated Metastatic Colorectal Cancer
This trial tests a new drug called JS212 in combination with other medicines for people with metastatic colorectal cancer that has not been treated before. It focuses on patients whose tumors are MSS or pMMR and aims to see if these combinations are safe and effective.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07504523RecruitingPhase 1
Personalized T-cell therapy for advanced colorectal cancer
This trial tests a custom-made T-cell treatment designed to target unique markers on your tumor. It's for people with advanced colorectal cancer who have run out of standard options or can't take them, and it aims to shrink tumors and improve survival.
Hangzhou, ZhejiangAges 18–70 - NCT07506005Recruiting
Stapler placement study for colorectal surgery
This trial tests if the placement of the stapler spike during colorectal surgery affects bleeding where the bowel is joined. It may help guide safer stapling techniques.
LinzAges Any age - NCT07506109RecruitingPhase 2
Study of sintilimab, ipilimumab, cetuximab, and dabrafenib for advanced colorectal cancer
This trial tests a combination of four drugs for people with a specific type of advanced colorectal cancer that has a BRAF V600E mutation and is microsatellite stable. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
Beijing, Beijing MunicipalityAges 18 years+
Hear when a new Colorectal trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for colorectal?
- Yes. Clin2 currently lists 1,218 recruiting colorectal studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a colorectal trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a colorectal trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.